Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 4/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.60 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133513 | 1.00 | GRIN1 (0.60) | GRIN1GRIN2BNR1I3CDK5CDK5R1 | |
| SCHEMBL13007746 | 1.00 | GRIN1 (0.60) | GRIN1GRIN2BNR1I3CDK5CDK5R1 | |
| SCHEMBL6812629 | 1.00 | GRIN1 (0.60) | GRIN1GRIN2BNR1I3CDK5CDK5R1 | |
| SCHEMBL30645499 | 0.83 | GRIN1 (0.58) | GRIN1GRIN2BNR1I3CDK5CDK5R1 | |
| SCHEMBL4834976 | 0.81 | GRIN1 (0.56) | GRIN1GRIN2BNR1I3CDK5CDK5R1 | |
| SCHEMBL3853829 | 0.81 | GRIN1 (0.41) | GRIN1GRIN2BNR1I3SHBG | |
| SCHEMBL4833938 | 0.81 | GRIN1 (0.56) | GRIN1GRIN2BNR1I3CDK5CDK5R1 | |
| SCHEMBL26304098 | 0.81 | GRIN1 (0.41) | GRIN1GRIN2BNR1I3SHBG | |
| SCHEMBL7353210 | 0.80 | GRIN1 (0.55) | GRIN1GRIN2BNR1I3CDK5CDK5R1 | |
| SCHEMBL374356 | 0.80 | GRIN1 (0.55) | GRIN1GRIN2BNR1I3CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11241446-B2 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200155576-A1 | 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20160244756-A1 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155576-A1 | 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | NR3C2, NR3C1, CYP11B1 | GRIN1 125/4885GRIN2B 12/4885NR1I3 34/4885 |
| US-11241446-B2 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | NR3C2, NR3C1, CYP11B1 | GRIN1 125/4885GRIN2B 12/4885NR1I3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.